News articles about PRA Health Sciences (NASDAQ:PRAH) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. PRA Health Sciences earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.2171514793651 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of PRA Health Sciences (NASDAQ:PRAH) traded down $1.28 during midday trading on Friday, hitting $90.06. 353,127 shares of the stock were exchanged, compared to its average volume of 411,893. The firm has a market cap of $5,707.10, a PE ratio of 50.31, a price-to-earnings-growth ratio of 1.26 and a beta of 0.41. PRA Health Sciences has a twelve month low of $54.08 and a twelve month high of $92.84. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same quarter last year, the company earned $0.64 EPS. The business’s revenue was up 23.7% on a year-over-year basis. equities analysts forecast that PRA Health Sciences will post 3.2 EPS for the current year.
A number of research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $103.00 price target on the stock in a report on Thursday. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 27th. Mitsubishi UFJ Financial Group initiated coverage on shares of PRA Health Sciences in a report on Friday, December 15th. They set an “overweight” rating and a $102.00 target price on the stock. Barclays initiated coverage on shares of PRA Health Sciences in a research report on Monday, December 11th. They set an “overweight” rating and a $94.00 price target for the company. Finally, Mizuho set a $87.00 price target on shares of PRA Health Sciences and gave the company a “buy” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $92.00.
In related news, EVP David W. Dockhorn sold 72,850 shares of the business’s stock in a transaction dated Friday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. Following the sale, the executive vice president now directly owns 72,850 shares in the company, valued at approximately $6,616,965.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The disclosure for this sale can be found here. Insiders sold a total of 150,815 shares of company stock worth $13,642,620 in the last three months. 2.10% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact PRA Health Sciences (NASDAQ:PRAH) Stock Price” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/14/pra-health-sciences-prah-given-coverage-optimism-rating-of-0-15.html.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.